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Abstract 
Neuroblastoma is one of the most common and most deadly childhood tumors. There is an unmet need to 
develop new therapeutic modalities for this malignancy that preferentially should be guided by our increasing 
knowledge of the biology of neuroblastoma. Proliferation and survival of neuroblastoma cells is critically 
dependent on suppression of the activity of the tumor suppressor protein p53, which is often mediated by 
increased activity of the MDM2 oncoprotein. Accordingly, small-molecule inhibitors of the interaction between 
MDM2 and p53 may provide a useful therapeutic option for the treatment of neuroblastoma by restoring the 
potent antitumor activity of wild-type p53. One of the most promising classes of selective inhibitors of the p53–
MDM2 interaction are the nutlins, which have been extensively studied over the last years in several tumor 
types, including neuroblastoma. We discuss here preclinical data that support the notion that nutlin drugs may 
offer therapeutic benefit for children with neuroblastoma, on condition that wild-type p53 is present. 
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NEUROBLASTOMA 
 
 Although childhood cancer is 
relatively rare, it is the second most 
important cause of death in children after 
accidents. Neuroblastoma is the most 
common type of malignancy in infants and 
the second most prevalent tumor in the age 
group of one to four years (1). This 
neoplasm originates from primitive cells of 
the sympathoadrenal lineage of the neural 
crest. Accordingly, neuroblastoma tumors 
can be located in the adrenal medulla and 
anywhere in the sympathetic nervous 
system (e.g., in the abdomen, chest, neck, 
and pelvis). A remarkable feature of 
neuroblastoma is that a subset of tumors 
regress spontaneously, but approximately 
half of all neuroblastoma patients have an 
aggressive disease and a survival 
probability below 40% (2). Factors that are 
predictive of a poor prognosis include 
advanced tumor stage, older age at 
diagnosis, unfavorable histology, poor 
grade of tumor differentiation or 
undifferentiated morphology, amplification 
of the MYCN oncogene, loss of the long 
arm of chromosome 11, and near-diploid 
or hypodiploid tumor cell DNA content 
(3). There is a clear unmet need to develop 
new treatment options for patients who are 
classified as high-risk at diagnosis and for 
patients who experience a relapse of their 
disease or who have tumors that are 
primarily resistant to conventional therapy. 
Ideally, these new treatment modalities 
should be biologically driven and should 
target central aberrations in tumor cells, 
while sparing normal cells. 
 
THE P53 PATHWAY 
 
 The biology of cancer is highly 
complex, but can in essence be reduced to 
a disruption of a small set of organizing 
principles (4). A limited number of core 
cellular pathways seem to control the 
proliferation and survival of normal cells 
and are therefore commonly altered in 
cancer cells. The most frequently 
inactivated protein in human cancer is 
probably p53 [encoded by the TP53 (p53) 
gene], which is an evolutionary conserved 
coordinator of stress responses in metazoan 
species that has evolved to function as a 
safeguard against malignant transformation 
in higher organisms with a longer life span 
(5). The p53 protein is stabilized and 
activated by a variety of stress signals, 
such as DNA damage, and binds then to 
specific response elements in the DNA. 
This results in the induction or repression 
of expression of target genes that provide 
the appropriate answer to the stress signal. 
Examples include induction of the 
expression of CDKN1A (p21
WAF1/CIP1
) and 
GADD45A, which encode proteins that 
mediate cell cycle arrest and DNA repair. 
If the stress stimulus persists or if the 
intensity of the stress is too severe, p53 
will induce the expression of target genes 
that elicit apoptosis or inhibit survival 
signaling, such as BAX, FAS, BBC3 
(PUMA), PMAIP1 (NOXA), and PTEN. 
The p53 transcription factor also induces 
gene expression alterations that result in 
cellular senescence, autophagy, antioxidant 
defense, regulation of metabolic pathways, 
and inhibition of angiogenesis. In addition, 
p53 has several transcription-independent 
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activities, like activation of mitochondrial 
apoptosis by binding to members of the 
BCL2 family of proteins. By means of 
these various mechanisms, p53 is capable 
of dealing with the cause of stress, 
repairing mild stress-induced damage, and 
eliminating severely damaged cells—
thereby providing a major roadblock to 
tumor development (6). 
 The strong tumor suppressor 
activity of p53 implies that tumor cells 
need to find a way to circumvent this 
failsafe program against oncogenesis. 
Approximately 50% of all human tumors 
bypass this barrier by acquiring an 
inactivating mutation in the p53 gene, 
whereas the other 50% of tumors suppress 
p53 activity by deregulating the normal 
function of other components in the p53 
pathway. The E3 ubiquitin ligase MDM2 is 
a central molecule in the p53 pathway that 
directly interacts with p53 and that keeps 
p53 under control by targeting the p53 
protein for proteasomal degradation and by 
blocking the transcriptional activity of p53 
(7). The negative regulation of p53 by 
MDM2 is very important under 
physiological conditions to prevent 
unwanted and potentially lethal p53 
activity, but a drawback of this tight 
control mechanism is that it also provides a 
tool to tumors to constitutively switch off 
the p53 protein. Indeed, tumors with wild-
type p53 can have an amplification of the 
MDM2 gene or increased expression or 
activity of the MDM2 protein to escape 
from p53-mediated growth control (8). In 
contrast to many adult cancers, 
neuroblastoma tumors rarely contain a p53 
mutation at diagnosis and at relapse (p53 
mutation prevalence of less than 2% and of 
15%, respectively) (9, 10). Compelling 
evidence indicates that oncogenic activity 
of MDM2, e.g. resulting from MYCN-
driven transactivation of MDM2 
expression, is the primary mechanism for 
inactivation of p53 in neuroblastoma (11). 
 
TARGETED INHIBITION OF THE 
P53–MDM2 INTERACTION BY 
NUTLIN DRUGS 
 
 The general importance of the 
interplay between MDM2 and p53 in 
tumor biology has stimulated the 
development of small-molecule inhibitors 
of the interaction between both proteins as 
a means to restore p53 activity in tumors 
with wild-type p53. Targeting protein–
protein interactions is, in general, 
challenging, as the interface of such 
interactions is typically large and flat and 
difficult to break by small molecules (12). 
However, in case of the p53–MDM2 
interaction, drug development efforts have 
taken advantage of the existence of an 
interaction hot spot suitable for drug 
binding. Crystallographic studies have 
shown that three hydrophobic amino acids 
of p53 (Phe
19
, Trp
23
, and Leu
26
) make the 
primary contact to MDM2 by binding to a 
deep hydrophobic cleft on the surface of 
this protein (13). Accordingly, a class of 
low-molecular-weight compounds with a 
cis-imidazoline backbone have been 
developed that have a similar spatial 
conformation as this triad of amino acids 
of p53 and that therefore can compete with 
p53 for binding to the hydrophobic pocket 
of MDM2 (Fig. 1) (14, 15). These small 
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Figure 1. Structural aspects of nutlin binding. A, chemical structure of nutlin-3. The groups depicted in red, 
green, and blue have a similar spatial conformation as the Phe
19
, Trp
23
, and Leu
26
 amino acid residues of the p53 
protein, respectively. B, competition between nutlin-2 (red) and p53 (green; only the relevant portion of the p53 
protein is shown) for binding to a hydrophobic pocket on the surface of the MDM2 protein (yellow). The nutlin 
drug binds to MDM2 at the same sites as the Phe
19
, Trp
23
, and Leu
26
 amino acid residues of p53. This binding 
model is derived from superimposition of the coordinates from the crystal structure of the nutlin-2–MDM2 
complex onto those of the p53–MDM2 complex [reproduced by permission of the publisher from (15)]. 
 
molecules, termed nutlins, were the first 
potent and selective inhibitors of the p53–
MDM2 interaction at the time of their 
discovery and have now progressed to 
clinical development in adult cancer 
patients. However, there is ample evidence 
that several pediatric malignancies may be 
good candidates for nutlin treatment as 
well. We discuss here some of the 
preclinical studies with nutlin-3, which is 
the most widely used nutlin compound in a 
research setting, that support the potential 
use of nutlin drugs in the treatment of 
neuroblastoma. 
 
IN VITRO ANTITUMOR ACTIVITY 
OF NUTLIN-3 IN NEUROBLASTOMA 
 
 A first study has been performed to 
examine the antitumor effects of nutlin-3 
as a single agent in a panel of 9 
neuroblastoma cell lines with either wild-
type or mutant p53 and with different 
genetic characteristics (16). Treatment with 
nutlin-3 was shown to selectively activate 
the p53 pathway in neuroblastoma cells 
with wild-type p53, as evidenced by 
accumulation of the p53 protein and by 
dose-dependent induction of expression of 
p53 target genes, like p21
WAF1/CIP1
, BAX, 
PUMA, TP53I3 (PIG3), and MDM2. This 
elicited a marked antiproliferative and 
cytotoxic effect through induction of both 
G1 cell cycle arrest and apoptosis. These 
treatment effects were observed 
irrespective of the presence or absence of 
commonly found genomic aberrations in 
neuroblastoma, such as MYCN 
amplification, 1p deletion, 3p deletion, 11q 
deletion, and 17q gain, which suggests that 
nutlin-3 may have broad applications in the 
treatment of neuroblastoma on condition 
that wild-type p53 is present. Interestingly, 
the few neuroblastoma cells that survived 
nutlin-3 treatment acquired a senescence-
like phenotype in cell line SK-N-SH or 
underwent neuronal differentiation in cell 
lines CLB-GA and NGP. The dependence 
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of these alternative nutlin-3 responses on 
p53 was demonstrated by the abrogation of 
these effects when p53 was silenced using 
lentivirus-mediated short hairpin RNA 
interference, consistent with targeted 
inhibition of the p53–MDM2 interaction. 
The occurrence of premature senescence 
and neuronal differentiation as drug-
induced response programs, in addition to 
G1 cell cycle arrest and apoptosis, 
uncovered a unique combination of 
antitumor treatment effects induced by a 
single targeted intervention. These 
pleiotropic activities of nutlin-3 to 
eliminate neuroblastoma cells may 
increase therapeutic efficacy and may 
possibly help to avoid the emergence of 
treatment resistance. In addition, the 
observation of tumor cell differentiation 
after therapy with nutlin-3 makes selective 
MDM2 inhibitors an attractive approach 
for the treatment of tumors that are arrested 
in their maturation, such as neuroblastoma. 
Several other studies have confirmed the 
potent antitumor activity of nutlin-3 or 
nutlin-3a (i.e., the purified active 
enantiomer of nutlin-3) in neuroblastoma 
cell lines with wild-type p53 and have 
demonstrated strong synergistic effects 
when this targeted therapy was combined 
with conventional chemotherapeutic agents 
both in neuroblastoma cell lines with wild-
type p53 and with mutant p53 (17-19). 
 
IN VIVO ANTITUMOR ACTIVITY OF 
NUTLIN-3 IN NEUROBLASTOMA 
 
 In vivo trials of nutlin-3 have been 
conducted in a context of chemoresistance 
(20), since most cases of treatment failure 
and patient mortality are attributable to the 
emergence of neuroblastoma cells that are 
resistant to conventional chemo-
therapeutics. New treatment options are 
therefore most urgently needed in the 
patient group with chemoresistant 
neuroblastoma tumors. It has been 
hypothesized that nutlin-3 may offer 
therapeutic benefit for the majority of 
patients with chemorefractory 
neuroblastoma, as most cases of 
chemoresistant neuroblastoma are not due 
to an inactivating p53 mutation (10). For 
example, elevated expression of drug 
efflux pumps, high expression of 
detoxifying enzymes, disequilibrium 
between apoptotic and survival signals, 
and defects in the extrinsic cell death 
signaling pathway are some of the 
mechanisms that can cause 
chemoresistance in neuroblastoma. In 
principle, these different forms of 
chemoresistance remain amenable, with 
the exception of p53 mutation, to 
therapeutic activity of nutlin-3. The 
antitumor effects of nutlin-3 have therefore 
been investigated in a well-established 
model system of acquired multidrug 
resistance that recapitulates several 
clinically relevant features of advanced-
stage and chemoresistant neuroblastoma 
tumors (e.g., increased proliferation, higher 
survival capacity, enhanced invasiveness, 
elevated tumorigenicity, and marked 
resistance to several chemotherapeutic 
agents and to irradiation) and that allows to 
study treatment effects in relationship to 
p53 status (wild-type or mutant p53) (20). 
In vitro studies demonstrated that treatment 
with nutlin-3 induced activation of the p53 
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pathway, G1 cell cycle arrest, and 
apoptosis in chemosensitive and 
chemorefractory neuroblastoma cells to a 
similar extent, on condition that wild-type 
p53 is present. Subsequently, mice with 
established subcutaneous chemorefractory 
neuroblastoma xenografts were treated 
with nutlin-3, which was administered 
orally at a dose of 200 mg/kg twice daily 
for three weeks or until euthanasia was 
required because of unacceptably large 
tumor size. This dosing schedule did not 
give rise to any overt sign of toxicity and 
reduced both the growth of the primary 
tumor and the extent of metastatic disease 
in liver and lungs when wild-type p53 was 
present. In contrast, and as expected, no 
treatment effects were observed in mice 
with p53-mutant chemorefractory 
neuroblastoma tumors. Investigation of 
mice carrying chemoresistant 
neuroblastoma xenografts with wild-type 
p53 demonstrated that oral administration 
of nutlin-3 for 36 hours induced activation 
of the p53 pathway and apoptosis in the 
xenograft tumors. Taken together, these 
data indicate that restoration of p53 
function by administration of nutlin-3 may 
provide a new therapeutic option for the 
treatment of metastatic and 
chemorefractory neuroblastoma tumors 
with wild-type p53. Convincing in vivo 
data that support the clinical development 
of this therapeutic approach have also been 
obtained when treatment with nutlin-3a 
was combined with the VEGF-blocking 
monoclonal antibody bevacizumab (21). 
This combination treatment cooperatively 
suppressed tumor growth and angiogenesis 
in an orthotopic mouse model of 
neuroblastoma, suggesting that selective 
MDM2 inhibitors may have therapeutic 
utility as adjuncts to antiangiogenic 
strategies. 
 
NUTLIN-3 AS A TOOL FOR 
PROBING THE P53 PATHWAY IN 
NEUROBLASTOMA CELLS 
 
 Understanding the mechanisms 
used by tumor cells to circumvent the p53-
driven antitumor barrier is important to 
select the right patient subsets for nutlin 
therapy. From the studies above and the 
targeted mechanism of action of nutlin-3, it 
is clear that wild-type p53 is a first 
prerequisite to obtain potent antitumor 
activity of nutlin-3. To gain more insight 
into additional determinants of the 
response to nutlin-3 in neuroblastoma 
cells, a detailed analysis has been 
performed in a set of 34 human 
neuroblastoma cell lines which were also 
characterized by sequencing of the p53 
gene and gene copy number analysis of 
MDM2, CDKN2A (p16
INK4a
/p14
ARF
), and 
MYCN (22). As expected, a highly 
significant difference in the sensitivity to 
nutlin-3 was observed between the 
neuroblastoma cell lines with wild-type 
p53 and the neuroblastoma cell lines with 
mutant p53. At 72 hours of treatment with 
nutlin-3, the median IC50 value (i.e., the 
concentration of nutlin-3 that caused 50% 
growth inhibition) was 4.6 µM for the 25 
neuroblastoma cell lines with wild-type 
p53 and >32 µM (the highest nutlin-3 
concentration tested) for the 9 lines with 
mutant p53. Marked reductions in cell 
viability were noted after nutlin-3 
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treatment in 23 out of the 25 
neuroblastoma cell lines with wild-type 
p53, indicating that downstream defects in 
the p53 pathway are uncommon in 
neuroblastoma. Neither amplification of 
the MDM2 gene nor MYCN amplification 
was predictive of the response to nutlin-3. 
However, deletion of the p16
INK4a
/p14
ARF
 
gene correlated with a reduced sensitivity 
to nutlin-3. Knockdown and 
overexpression experiments demonstrated 
that the expression levels of p14
ARF
, but 
not of p16
INK4a
, sensitize neuroblastoma 
cells to nutlin-induced apoptosis. This 
suggests that p14
ARF
 is not just an 
upstream regulator of the p53 protein, but 
also actively provides a coactivating signal 
for driving the p53 response towards 
apoptosis. Collectively, this study yields 
several insights into the spectrum of p53 
pathway lesions in neuroblastoma cells that 
could be useful for the clinical translation 
of therapeutic strategies aimed at 
restoration of p53 function. It remains to 
be determined in clinical trials whether 
treatment with nutlin drugs will result in 
the acquisition of p53 mutations and 
p14
ARF
 loss by tumor cells, but these data 
already provide sufficient evidence to 
stimulate the preclinical development of 
complementary therapeutic approaches that 
reactivate mutant p53 and counteract 
p14
ARF
 defects. Interestingly, an 
independent study has also identified the 
expression levels of MYCN as a factor that 
determines the response of neuroblastoma 
cells to nutlin-3 and to another inhibitor of 
the p53–MDM2 interaction, MI-63 (23). 
The authors of this study therefore 
speculated that selective MDM2 inhibitors 
may be particularly effective in the 
treatment of high-risk MYCN-amplified 
neuroblastoma. The occurrence of a strong 
apoptotic response in MYCN-amplified 
neuroblastoma cells treated with nutlin-3 
has been attributed to a tumor type–
dependent induction of HIPK2, which is a 
p53-activating proapoptotic kinase (24), 
and to repression of the β-galactoside–
binding protein galectin-3 (25). However, 
it is not yet clear whether MYCN 
amplification or high MYCN expression 
will be a clinically useful biomarker for 
predicting treatment outcome, as several 
authors have failed to detect a significant 
better response to nutlin-3 upon MYCN 
induction or in MYCN-amplified 
neuroblastoma cells compared to MYCN-
nonamplified neuroblastoma cells (16, 17, 
22, 26). The reasons for these contrasting 
findings are unclear and may, for instance, 
relate to the use of different model 
systems. Further study is clearly needed to 
clarify this issue. 
 
CONCLUSIONS 
 
 The existing preclinical data lend 
strong support to the view that nutlin drugs 
may be a viable therapeutic option for 
patients with neuroblastoma. However, 
several issues still need to be addressed 
prior to introduction of these drugs in the 
clinic. For instance, the in vivo activity of 
nutlin-3 against neuroblastoma has at 
present only been investigated using tumor 
xenograft modeling in nude mice and not 
yet in immunocompetent transgenic mouse 
models of neuroblastoma. There is also a 
clear need to define the best combinatorial 
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treatment regimen for clinical 
implementation and to identify 
pharmacodynamic biomarkers for 
noninvasive monitoring of treatment 
response. Another important requirement is 
that nutlin drugs are found to be safe and 
tolerable in phase I clinical trials in adult 
cancer patients, which are currently 
ongoing. If these outstanding questions can 
be answered in a satisfactory way, we hope 
that the concept of reactivation of wild-
type p53 may mature to a new therapeutic 
avenue for the treatment of children with 
neuroblastoma. 
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